AstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: APAstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: AP
AstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: AP

Hong Kong health experts say delay to AstraZeneca vaccine effort will not hinder government plans to secure Covid-19 shots

  • With so many other candidates in late development, the city has plenty of options, says Professor David Hui
  • Encountering side effects is expected during stage three trials of a drug, notes Professor Yuen Kwok-yung

Topic |   Coronavirus pandemic
AstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: APAstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: AP
AstraZeneca and Oxford aim to enrol as many as 50,000 participants for late-stage trials of its vaccine candidate. Photo: AP
READ FULL ARTICLE
Close
We need your support

Advertising helps us continue to provide quality content. Help support us by disabling your adblocker on our site.

How to whitelist us:
  1. 1
    Click on the AdBlock icon at the top right corner of your browser.
    For iOS, go to Settings/Safari/Content Blockers and turn it off.

    For Android, go to your Ad blocker app/Settings and turn it off.
  2. 2
    Click Enabled on this site until the text reads Disabled on this site.
  3. 2
    Click the cross icon on the top right corner to close this window and refresh the page.
  4. 3
    Click the cross icon on the top right corner to close this window and refresh the page.